Typewriter Therapeutics, Inc.
StreetZero Signal 79
About Typewriter Therapeutics, Inc.
Typewriter Therapeutics, Inc. is a Cambridge, Massachusetts-based biotechnology company developing safe, durable and re-dosable RNA-based genetic medicines. The company focuses on gene writing and in vivo CAR-T therapies for patients with cancer, autoimmune diseases, and severe genetic disorders. It emerged from stealth in September 2026 and maintains operations in both Cambridge, MA and Tokyo.
LATEST FUNDINGSeries A
$56.3M
Announced 2026-09-21
TOTAL RAISED$61M
IN THE NEWS
- 🔗 Typewriter Therapeutics - 2026 Company Profile, Funding & Competitors - Tracxn
- 🔗 Typewriter Therapeutics - 2026 Company Profile, Funding & Competitors - Tracxn
- 🔗 Typewriter Therapeutics Emerges from Stealth with $56 Million Series A Financing to pursue in vivo CAR T medicines
- 🔗 Typewriter Therapeutics Emerges from Stealth with $56 Million Series A Financing to pursue in vivo CAR T medicines - Typewriter Therapeutics
- 🔗 Typewriter Therapeutics - Products, Competitors, Financials, Employees, Headquarters Locations
EMPLOYEES—
FOUNDED2022
HQCambridge, MA, United States
Industry
Biotechnology
Tags
BiotechnologyGene TherapySeries A
Key highlights
- Emerged from stealth in September 2026 with $56 million Series A financing.
- Developing RNA-based gene writing platform for in vivo CAR-T and genetic disease therapies.
- Backed by AN Venture Partners, RA Capital Management, ANRI, Gemseki, and SBI US Gateway Fund.
- Targeting cancer, autoimmune diseases, and severe genetic disorders with re-dosable genetic medicines.
- Total funding reaches $61 million across two rounds per Tracxn data.
Ask StreetZero about Typewriter Therapeutics, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account